total assets, as reflected in the Condensed Consolidated Balance Sheets. See Note 6, Investments, for further information regarding equity method investments, and Net cash used in investing activities in the Condensed Consolidated Statements of Cash Flows for further information regarding capital expenditures.
7
The following table provides segment revenues, significant segment expenses, other segment items, reported segment net income (loss) and a reconciliation of segment net income (loss) to the Company’s total consolidated net income (loss) for the three months ended March 31, 2025 and 2024 (in millions):
____________
(1)
During both the three months ended March 31, 2025 and 2024, amortization of our finite-lived intangible assets was $
1.2
billion, which was primarily included in Cost of sales in the Condensed Consolidated Statements of Income (Loss). In addition, during the three months ended March 31, 2025 and 2024, we recognized depreciation and right-of-use asset amortization of $
209
million and $
201
million, respectively.
(2)
During the three months ended March 31, 2025 and 2024, manufacturing cost of sales included amortization of step-up to fair value of inventory acquired in business combinations of $
363
million and $
693
million, respectively.
(3)
Other segment items included in Segment net income (loss) primarily consisted of fair value adjustments on equity securities (see Note 6, Investments) and net impairment charges on intangible assets (see Note 8, Goodwill and other intangible assets).
8
3.
Revenues
We operate our business in
one
operating segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW product sales relates to products sold in Europe.
Revenues were as follows (in millions):
_______
(1)
TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.
(2)
Consists of product sales of our non-principal products.
(3)
Hedging gains and losses, which are included in product sales, were not material for the three months ended March 31, 2025 and 2024.
9
4.
Income taxes
The effective tax rate for the three months ended March 31, 2025 was
12.3
% compared with (
66.2
)% for the prior year period.
The increase in our effective tax rate for the three months ended March 31, 2025, was primarily due to the change in earnings mix as a result of net unrealized gains in the first quarter of 2025 compared to net unrealized losses in the first quarter of 2024 on equity investments (primarily BeiGene). See Note 6, Investments
—BeiGene, Ltd.
The effective tax rates differ from the federal statutory rate primarily due to the impact of the jurisdictional mix of income and expenses. Substantially all of the benefit to our effective tax rate from foreign earnings results from